PMID: 8584612Oct 1, 1995Paper

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

Psychopharmacology
J A Den BoerO N Srivastava

Abstract

In the present open study the effects of the D1-dopamine antagonist SCH 39166 on positive and negative symptoms of schizophrenia (DSM-IIIR) were investigated. SCH 39166 was given orally according to a fixed dosage schedule (day 1: 25 mg b.i.d; day 4: 50 mg b.i.d.; day 7: 100 mg b.i.d.; day 18: 200 mg b.i.d.; day 21: 225 mg b.i.d.). Seven patients completed 2 weeks, and five patients completed the study. The reason for premature withdrawal was lack of efficacy or refusal to take SCH 39166. In none of the patients a reduction of the BPRS or CGI score was found. As measured with the PANSS, a significant reduction was observed in the score of the negative subscale, whereas the positive symptoms scale and general psychopathology score remained unaffected. Akathisia, rigidity and hypokinesia were reported occasionally, although only mild in severity. The results of the present study do not support the hypothesis that D1-dopamine antagonists are clinically effective antipsychotics in schizophrenia, considering the fact that SCH 39166 had no effect on positive symptoms. The present study provides circumstantial evidence for an effect of SCH 39166 on negative symptoms.

References

Jan 1, 1992·Progress in Neuro-psychopharmacology & Biological Psychiatry·M R Lynch
Apr 29, 1992·European Journal of Pharmacology·R D McQuadeA Barnett
Sep 1, 1989·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B A EllenbroekA R Cools
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Feb 9, 1993·European Journal of Pharmacology·E P PrinssenA R Cools
Mar 1, 1993·Pharmacology & Toxicology·H HallG Sedvall

❮ Previous
Next ❯

Citations

Oct 1, 1995·Psychopharmacology·T R Barnes, J Gerlach
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Shitij KapurMing Li
Nov 14, 1997·Neuroscience and Biobehavioral Reviews·S A JosselynR J Beninger
Jun 5, 1998·Trends in Pharmacological Sciences·M S LidowP S Goldman-Rakic
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Oct 24, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dara M CannonWayne C Drevets
Jan 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Lena ScottAnita Aperia
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·W W Fleischhacker
Jul 6, 2014·BioMed Research International·Benjamin RollandRégis Bordet
Sep 4, 2008·Expert Opinion on Emerging Drugs·Ofer AgidGary Remington
Jan 3, 2016·Psychiatry Research·Caroline GurvichSusan L Rossell
Mar 8, 2016·Biological Psychiatry·Amy F T ArnstenRichard B Mailman
Jan 20, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L Lladó-PelfortP Celada
Sep 4, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lukasz BojarskiUrszula Wojda
Jul 25, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rodrigo D PazKuei Y Tseng
Dec 20, 2003·Annals of the New York Academy of Sciences·Marc LaruelleAnissa Abi-Dargham
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle
Jun 24, 2015·British Journal of Pharmacology·Laura J MosherMarco Bortolato
Oct 10, 2014·Psychiatry and Clinical Neurosciences·Ichiro KusumiYoshito Takahashi
Dec 29, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Rudi HwangJames L Kennedy
May 28, 2011·Acta Physiologica Hungarica·Julia Fedotova, N Ordyan
Feb 15, 2014·Current Opinion in Pharmacology·Marc Laruelle
Apr 17, 1999·American Journal of Medical Genetics·H KojimaK Abe
Sep 10, 2005·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Charles R Yang, Long Chen
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Nov 10, 2006·Journal of Psychopharmacology·Rudi HwangJames L Kennedy
Oct 29, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Anissa Abi-Dargham, Holly Moore
Jan 1, 1996·Journal of Religion and Health·David M Matzko
Apr 9, 2019·The International Journal of Neuropsychopharmacology·Per StenkronaLars Farde
Apr 23, 2014·Journal of Neurogenetics·Tripti Gupta, Angela Giangrande
Oct 7, 2008·Applied and Environmental Microbiology·Parthiban RajasekaranStephen M Boyle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here